vidarabine has been researched along with Leukemia, Myelomonocytic, Juvenile in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Geng, L; Li, G; Liu, H; Qiang, P; Song, K; Sun, Z; Tang, B; Tong, J; Wan, X; Yao, W; Zhang, L; Zhang, S; Zhang, X; Zhu, X | 1 |
| Atsuta, Y; Cho, Y; Hama, A; Hasegawa, D; Hashii, Y; Kakuda, H; Kato, K; Kato, M; Koh, K; Noguchi, M; Sakaguchi, H; Sato, A; Sato, M; Shimada, H; Takahashi, Y; Terui, K; Watanabe, K; Yabe, M; Yoshida, N | 1 |
| Cairo, MS; Cooper, T; Dang, H; Dvorak, CC; Gao, Y; Grupp, SA; Hirsch, B; Kahwash, S; Loh, ML; Mazor, T; Mehta, PA; Olshen, AB; Parker, JS; Patel, N; Pei, Q; Raimondi, S; Satwani, P; Skeens, M; Stieglitz, E; Wall, D | 1 |
| Guilcher, GM; Lewis, VA; Moorjani, R; Truong, TH | 1 |
| Inagaki, J; Kakuda, H; Kudo, K; Kurosawa, H; Manabe, A; Ohtsuka, Y; Sakashita, K; Watanabe, K; Yabe, H; Yabe, M; Yoshida, N | 1 |
| Alonzo, TA; Arceci, RJ; Balis, FM; Bunin, NJ; Castleberry, RP; Cheng, JW; Cooper, TM; Emanuel, PD; Gerbing, RB; Jayaprakash, N; Liu, YL; Loh, ML; Stieglitz, E; Ward, AF; Widemann, BC | 1 |
| Adachi, S; Kobayashi, C; Kojima, S; Kurosawa, H; Manabe, A; Nakahata, T; Nakazawa, Y; Nara, T; Ogawa, C; Ohtsuka, Y; Osugi, Y; Sako, M; Tokuyama, M; Yabe, H; Yabe, M; Yanagimachi, M | 1 |
2 trial(s) available for vidarabine and Leukemia, Myelomonocytic, Juvenile
| Article | Year |
|---|---|
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.
Topics: Busulfan; Child; Child, Preschool; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Leukemia, Myelomonocytic, Juvenile; Male; Myeloablative Agonists; Prognosis; Transplantation Conditioning; Vidarabine | 2018 |
Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Isotretinoin; Leukemia, Myelomonocytic, Juvenile; Male; Middle Aged; Quinolones; Survival Rate; Vidarabine | 2015 |
5 other study(ies) available for vidarabine and Leukemia, Myelomonocytic, Juvenile
| Article | Year |
|---|---|
Clinical outcome of cord blood transplantation for nine children with juvenile myelomonocytic leukemia receiving fludarabine-busulfan-cyclophosphamide-based conditioning.
Topics: Antineoplastic Agents; Busulfan; Child; Child, Preschool; China; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Humans; Infant; Leukemia, Myelomonocytic, Juvenile; Male; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia: A Report from the Japan Society for Hematopoietic Cell Transplantation.
Topics: Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Japan; Leukemia, Myelomonocytic, Juvenile; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2020 |
Myeloablative BU, fludarabine, antithymocyte globulin and low-dose TBI in the treatment of juvenile myelomonocytic leukaemia with allogeneic haematopoietic cell transplantation.
Topics: Antilymphocyte Serum; Busulfan; Child, Preschool; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myelomonocytic, Juvenile; Myeloablative Agonists; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2015 |
Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Leukemia, Myelomonocytic, Juvenile; Male; Melphalan; Retreatment; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2015 |
A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.
Topics: Administration, Oral; Busulfan; Child; Child, Preschool; Female; History, Ancient; Humans; Immunosuppressive Agents; Leukemia, Myelomonocytic, Juvenile; Male; Melphalan; Pilot Projects; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |